Mankind Pharma draws rush of buy calls on 57% jump since IPO

Investors are scrambling to purchase shares in drug and condom maker, Mankind Pharma Ltd., which has had the most analyst coverage of any new Indian stock in 12 years after its highly successful May IPO. The shares have surged by 57% since being listed, driving its market value above $8bn. The firm has attracted nine buy ratings and one hold. While the majority of analysts recommend buying shares, the consensus price target is already 10% below the current value due to its stellar run.

More To Explore

Advertiser Disclosure

Great-investor.com helps users across the globe to find out The latest news, Guides, and Info about finance and investments. Furthermore, our content and research teams do not participate in any advertising planning nor are they permitted access to advertising campaign data.

Disclaimer

It is our organization’s primary mission to provide reviews, commentary, and analysis that are unbiased and objective. While great-investor.com has some data verified by industry participants, it can vary from time to time. Operating as an online business, this site may be compensated through third party advertisers. Our receipt of such compensation shall not be construed as an endorsement or recommendation by great-investor.com, nor shall it bias our reviews, analysis, and opinions. Please see our General Disclaimers for more information.

The information on this website does not constitute investment advice or a recommendation or a solicitation to engage in any investment activity. This website and its content are not intended for residents of the UAE, US, Canada, Australia, UK, Russia, North Korea, China, Japan, Hong Kong, Singapore and Iran.

Top10 International FZ LLE | 17th Floor, Creative Tower | 4422 | Fujairah | TRN: 100608946800003